Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Accounts Payable & Accrued Expense : €27.1 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Accounts Payable & Accrued Expense?

Biocytogen Pharmaceuticals (Beijing) Co's quarterly accounts payable & accrued expense declined from Dec. 2023 (€39.2 Mil) to Jun. 2024 (€32.4 Mil) and declined from Jun. 2024 (€32.4 Mil) to Dec. 2024 (€27.1 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual accounts payable & accrued expense declined from Dec. 2022 (€51.2 Mil) to Dec. 2023 (€39.2 Mil) and declined from Dec. 2023 (€39.2 Mil) to Dec. 2024 (€27.1 Mil).

Biocytogen Pharmaceuticals (Beijing) Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Accounts Payable & Accrued Expense Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

33.54

49.76

51.19

39.20

27.12

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial				51.19	43.62	39.20	32.36	27.12

Biocytogen Pharmaceuticals (Beijing) Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

02315:Hong Kong

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines